Harbinger Research Releases Research Report on Vycor Medical, Inc.
May 01 2012 - 1:58PM
Marketwired
Vycor Medical, Inc. (OTCBB: VYCO), a
Florida-based corporation, is pleased to announce today that
Harbinger Research has released a new comprehensive report
regarding its analysis of the Company and its two subsidiaries. The
report can be accessed on the Harbinger Research website directly
at http://www.harbingerresearch.com/clients/vyco.
The report states that Harbinger Research "are initiating
coverage of Vycor with a Strong Buy rating and a target price range
of $0.05 per share" noting that Vycor's neurosurgical ViewSite
Brain Access System leads to "improved clinical outcomes, shorter
surgeries, and shorter recovery times; in some cases this product's
superior attributes have allowed brain surgeons to successfully
perform surgeries that would have otherwise been considered
inoperable" and that they are "most excited about the long-term
potential of the NovaVision subsidiary, as its products have no
real competition and address a global market that could be up to
$20B in size." Furthermore they state that "both NovaVision and
ViewSite have strong patent protection and backing from the
scientific community, and both are FDA 510(k) cleared for sale in
the United States."
David Cantor, President of Vycor Medical, stated that management
is pleased by the positive outlook for the Company reflected in the
report.
About Vycor Medical Inc.:
With corporate headquarters in Boca Raton, FL, Vycor Medical,
Inc. (OTCBB: VYCO) is a medical device company committed to making
neurological brain, spinal and other surgical procedures safer and
more effective. The company's flagship, Patent Pending ViewSite™
Surgical Access Systems represent an exciting new minimally
invasive access and retraction system that holds the potential for
speedier, safer and more economical brain, spinal and other
surgeries and a quicker patient discharge. Vycor's innovative
medical instruments are designed to optimize neurosurgical site
access, reduce patient risk, accelerate recovery, and add tangible
value to the professional medical community. Vycor is ISO
13485:2003 compliant, has FDA 510(k) clearance for brain and spine
surgeries, and CE Marking and HPB licensing in Canada.
Vycor Medical's subsidiary, NovaVision, Inc., researches,
develops and provides science-driven vision-based neurostimulation
therapy and other medical technologies that help to improve sight
in patients with neurological vision impairments. The company's
proprietary, Visual Restoration Therapy (VRT) platform is
clinically supported to improve lost vision resulting from stroke,
traumatic brain injury ("TBI"), or other acquired brain injury, and
has been 510(k) cleared to be marketed in the US by the FDA. VRT
can be prescribed by any ophthalmologist, optometrist, neurologist
or physiatrist. NovaVision, through its subsidiary Sight Science,
also provides Neuro-Eye Therapy (NeET), aimed at increasing visual
sensitivity deep within the field defect. NovaVision also provides
a fully portable and ADA-compliant Head Mounted Perimeter (HMP™)
which aids in the detection and measurement of visual field
deficits
For the latest information on the company, including media and
other coverage, and to learn more, please go online at
www.vycormedical.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute
forward-looking statements or statements which may be deemed or
construed to be forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The words
"forecast", "anticipate", "estimate", "project", "intend",
"expect", "should", "believe", and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements involve, and are subject to known and unknown risks,
uncertainties and other factors which could cause Vycor Medical's
actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in Vycor Medical's filings with
the U.S. Securities and Exchange Commission. All forward-looking
statements attributable to Vycor Medical herein are expressly
qualified in their entirety by the above-mentioned cautionary
statement. Vycor Medical disclaims any obligation to update
forward-looking statements contained in this estimate, except as
may be required by law.
Lenny Sorin Vycor Medical, Inc. 561-558-2000 Email Contact
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Sep 2023 to Sep 2024